Comparing enoxaparin injection sites in adults with severe obesity
Part of Heart & circulation clinical trials.
This study looks at how the blood thinner enoxaparin (Lovenox) is absorbed in people with severe obesity when injected into two different body areas. It aims to see if the standard preventive dose works well, potentially improving clot prevention for people your size.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old.
- Your body mass index (BMI) must be over 40, which is considered severe obesity.
- You need to be at risk of blood clots, which your doctor can confirm with a score called the Padua score.
- You cannot be taking full-dose blood thinners.
- Your kidney function must be adequate (not severely reduced).
- You must not be pregnant or have conditions that increase bleeding risk (like active bleeding, stomach ulcer, or low platelets).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two doses of a blood thinner (enoxaparin) to see which better prevents blood clots in patients with severe injuries who are in the intensive care unit. It helps doctors choose the best dose to keep you safe and healthy.
This study tests a new injection called SRSD107 to see if it prevents blood clots after knee replacement surgery, compared to a standard blood thinner (enoxaparin). It might be an option if you are having a planned knee replacement and are otherwise healthy.
This study compares a new version of the blood-thinning drug enoxaparin (called a biosimilar) to the standard brand, Clexane. If you are a healthy adult, you might be eligible to participate, which helps ensure the new drug works the same way.
This trial compares two different doses of a blood-thinning medicine to prevent blood clots after weight-loss surgery. It aims to find which dose is safer and more effective for people with higher body weight.
This study compares two blood-thinning medications, rivaroxaban (a pill) and enoxaparin (a shot), to prevent dangerous blood clots after weight-loss surgery. If you are scheduled for bariatric surgery, this trial could help determine which approach works better for someone like you.
This study looks at how a common blood thinner (enoxaparin) is processed in the body of ICU patients with kidney failure, including those on dialysis. The goal is to make sure the dose is safe and effective for preventing blood clots in this fragile group.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.